- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02533050
Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With CPAP (CAPCORSAS)
Attentional Capacity and Working Memory in Coronary Artery Disease Patients: Impact of the Presence of a Sleep Apnea Syndrome and Chronic Effects of Treatment With a Continuous Positive Airway Pressure System (CPAP). Etude CAPCORSAS
The presence of Obstructive Sleep Apnea Syndrome (OSAS) has a high frequency in patients victims of a coronary artery disease (CAD) (myocardial infarction, revascularization). Unlike patients seen in a sleep Laboratory with an impact on daytime functioning, CAD apneic patients do not complain in their daytime functioning. The objective of this study is to explore whether the objective cognitive assessment measures may be a good marker of the efficacy of CPAP treatment given to non-sleepy apneic CAD patients.
Coronary patients with an AHI between 15 and 40 / h will be treated (or not) after randomization with CPAP treatment. The expected results are: CPAP apneic coronary patients should have a positive impact on cognitive performance, particularly on attention span and working memory measured by improvement in the Paced Auditory Serial Addition Test score (PASAT score).
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Saint-etienne, Francia, 42000
- CHU de Saint-Etienne
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Patient admitted to the Clinical Physiology Department of Exercise of the Saint Etienne University Hospital (myocardial infarction, coronary stenting or coronary artery bypass) and referred for care in cardiac rehabilitation
- A native French speaker
- No daytime sleepiness (ESS <or = 10)
- Signature of informed consent by the patient
Exclusion Criteria:
- Patients with a previous diagnosis of sleep apnea syndrome
- Patients with severe heart failure (stage III and IV of the NYHA)
- Patients with a neurodegenerative disease or other known cognitive disorders
- Presence of progressive disease other than coronary artery disease (cancer for example)
- Patients participating in other research that can change their cognitive function or drowsiness
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Patients treated
Patients with CAD and SAS.
This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an Epworth sleepiness score (ESS) <10.
After randomization, they will be treated with CPAP treatment.
|
Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
|
|
Sin intervención: Patients non-treated
Patients with CAD and SAS.
This patients should have an apnea-hypopnea index (AHI) between 15 and 40, and an ESS <10.
After randomization, they will be not treated.
|
|
|
Sin intervención: Control group
Patients with CAD but without SAS (AHI<15).
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
PASAT-4sec test score
Periodo de tiempo: Day 120
|
The PASAT is a measure of cognitive function that assesses auditory information processing speed and flexibility, as well as calculation ability.
Single digits are presented every 4 seconds and the patient must add each new digit to the one immediately prior to it.
The score for the PASAT is the total number correct out of 60 possible answers.
|
Day 120
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Score Mini Mental State (MMS)
Periodo de tiempo: Day 120
|
It is a score obtained in psychometric tests.
This is a series of 30 questions that assesses cognitive and mnemonic ability of a person.
|
Day 120
|
|
Mean time (ms) obtained in a Continus Performance Test
Periodo de tiempo: Day 120
|
It is an other score obtained in psychometric tests.
It measures a person's sustained and selective attention (associated with impulsivity and distractibility).
|
Day 120
|
|
Percentage (%) obtained in a test measurement of the reaction time
Periodo de tiempo: Day 120
|
It is an other score obtained in psychometric tests.
It is a psychometer vigilance test.
|
Day 120
|
|
Mean time (ms) obtained in a test measurement of the reaction time
Periodo de tiempo: Day 120
|
It is an other score obtained in psychometric tests.
It is a psychometer vigilance test.
|
Day 120
|
|
Percentage (%) for a N-back working memory task
Periodo de tiempo: Day 120
|
It is an other score obtained in psychometric tests.
The subject is presented with a sequence of stimuli, and the task consists of indicating when the current stimulus matches the one from n steps earlier in the sequence.
|
Day 120
|
|
Average time (ms) for a N-back working memory task
Periodo de tiempo: Day 120
|
It is an other score obtained in psychometric tests.
The subject is presented with a sequence of stimuli, and the task consists of indicating when the current stimulus matches the one from n steps earlier in the sequence.
|
Day 120
|
|
AHI
Periodo de tiempo: Day 120
|
It is the number of apnea and hypopnea per hour.
It determined by polysomnography.
|
Day 120
|
|
Mean nocturnal oxygen saturation (%)
Periodo de tiempo: Day 120
|
It is a percentage index of hypoxemia measured by a polysomnography.
|
Day 120
|
|
Minimal nocturnal oxygen saturation (%)
Periodo de tiempo: Day 120
|
It is an other percentage index of hypoxemia measured by a polysomnography.
|
Day 120
|
|
The oxyhemoglobin desaturation index
Periodo de tiempo: Day 120
|
It is an other index of hypoxemia measured by a polysomnography.
It is expressed in desaturations / hour
|
Day 120
|
|
The time (min) spent with a SaO2 below 90%
Periodo de tiempo: Day 120
|
The arterial oxygen saturation (SaO2)is an other index of hypoxemia measured by a polysomnography.
|
Day 120
|
|
Sleep fragmentation
Periodo de tiempo: Day 120
|
It is determined by a polysomnography.
|
Day 120
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Procesos Patológicos
- Enfermedades cardíacas
- Enfermedades cardiovasculares
- Enfermedades Vasculares
- Enfermedades del Sistema Nervioso
- Enfermedades de las vías respiratorias
- Arteriosclerosis
- Enfermedades arteriales oclusivas
- Trastornos de la respiración
- Trastornos del Sueño Intrínsecos
- Disomnias
- Trastornos del sueño y la vigilia
- Enfermedad
- Signos y Síntomas Respiratorios
- Enfermedad de la arteria coronaria
- Isquemia miocardica
- Enfermedad coronaria
- Síndromes de apnea del sueño
- Apnea del Sueño Obstructiva
- Síndrome
- Apnea
- El síndrome coronario agudo
Otros números de identificación del estudio
- 1308171
- 2013-A01635-40 (Otro identificador: ANSM)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .